GC Pharma Up 1.88% as of Now... Institutions Net Sell 55,463 Shares Over Past 5 Days

As of 2:30 p.m. on November 12, GC Pharma is trading at 379,000 KRW, up 1.88% from the previous day. The trading volume stands at 500,918 shares, which is 51.55% of the previous day's trading volume. GC Pharma is known as a pharmaceutical company specializing in blood products and vaccines.

On November 11, Koo Wansung, a researcher at NH Investment & Securities, stated, "GC Pharma has signed a CMO contract with the global coalition CEPI (Coalition for Epidemic Preparedness Innovations). With supply expected to begin in the first half of next year, a quantum leap in profit is anticipated. The CMO contract value of 2.862 trillion KRW is reflected. In addition, multiple R&D momentum drivers are expected in the fourth quarter, including approval for GreenGene F (hemophilia) in China, approval for Hunterase ICV in Japan, and an application for approval of IVIG (immune disorders) in the United States. Therefore, we maintain GC Pharma as our top pick in the pharmaceutical sector." He set the target price for GC Pharma at 510,000 KRW.

Over the past five days, individual investors have made a net purchase of 51,474 shares of GC Pharma. Foreign investors and institutions have made a net purchase of 17,126 shares and a net sale of 55,463 shares, respectively.

※ Source: AI investment assistant AI Rassiro

※ This article was automatically generated in real time by a news automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.